GREATER CHINA Strategy Alpha Picks: May Conviction Call: Adding CR Beer, Crystal, Geely, Haier, Kuaishou, Ningbo Tuopu, Pinduoduo, Shenzhou, and Tencent to our BUY list, closing out SELL calls. INDONESIA Strategy Alpha Picks: Slight Outperformance In A Bear Market: Our picks are BSDE, TLKM, ACES, BBTN, CMRY, SIDO, JSMR and AKRA. MALAYSIA Strategy Alpha Picks: Well-Positioned For 1Q Results Season: Our April picks again beat the KLCI. May 24 picks: GENM, Inari, Mah Sing, MrDIY, MYEG, Press Meta...
GREATER CHINA Strategy Alpha Picks: May Conviction Call Adding CR Beer, Crystal, Geely, Haier, Kuaishou, Ningbo Tuopu, Pinduoduo, Shenzhou, and Tencent to our BUY list, closing out SELL calls. Small-Mid Cap Monthly Reiterate BUY on Crystal International. Sector Automobile Weekly: EV sales pick up; take...
Q1 sales beat our forecast and consensus due to higher product-related royalties and solid Epkinly sales, while the operating profit margin was softer than expected owing to higher opex. Genmab reiterated the 2024 guidance for sales of DKK18.7bn–20.5bn, opex of DKK12.4bn–13.4bn, and operating profit of DKK4.6bn–7.1bn. We expect a strong pipeline of news flow in 2024. We reiterate our BUY and DKK2,630 target price.
Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, with a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2024An additional Phase 3 clinical trial was initiated...
Danone acquires Functional Formularies Press release – Paris, May 01, 2024 Danone acquires Functional Formularies Danone announces today it has successfully completed the acquisition of Functional Formularies, a leading whole foods tube feeding business in the US, from Swander Pace Capital. As part of the Renew Danone strategy, this acquisition strengthens Danone’s Medical Nutrition portfolio in the US by further expanding its enteral tube feeding ranges. Juergen Esser, Deputy CEO and CFO, said: “As a global leader in Medical Nutrition, we are delighted to welcome Functional Formularie...
Danone acquiert Functional Formularies Communiqué de presse – Paris, le 1er mai 2024 Danone acquiert Functional Formularies Danone annonce aujourd’hui avoir réalisé l’acquisition de Functional Formularies, leader aux Etats-Unis de l’alimentation par sonde à base d’aliments, auprès de Swander Pace Capital. Dans le cadre de la stratégie Renew Danone, cette acquisition renforce le portefeuille de Danone en Nutrition Médicale aux Etats-Unis, élargissant sa gamme d’alimentation entérale. Juergen Esser, Directeur Général Adjoint et Directeur Financier : « Nous sommes ravis d'accueillir Funct...
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark; April 30, 2024 – (Nasdaq: GMAB) and (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) f...
Transactions in Connection with Share Buy-back Program Genmab Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 22, 2024 to April 26, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 408,701 836,159,5...
Danone successfully issues a €700 million bond Press Release – Paris, April 26, 2024 Danone successfully issues a €700 million bond Danone announces that it has issued today a €700 million bond with a 6-year maturity and a 3.481% coupon. In line with the company’s active liquidity management, this issue enables Danone to enhance its funding flexibility while extending the maturity of its debt. The settlement is expected to take place on May 3, 2024 and the bonds will be listed on Euronext Paris. The bond issue was widely subscribed by a diversified investor base, confirming the high c...
Danone réalise avec succès une émission obligataire de 700 millions d’euros Communiqué de presse – Paris, le 26 avril 2024 Danone réalise avec succès une émission obligataire de 700 millions d’euros Danone annonce avoir réalisé aujourd’hui le placement d’une émission obligataire d’un montant de 700 millions d’euros, avec une maturité de 6 ans et assortie d’un coupon de 3,481%. S’inscrivant dans le cadre de la gestion active de sa liquidité, cette émission permet à Danone d’accroître sa flexibilité financière tout en allongeant la maturité de sa dette. Le règlement-livraison est prévu le...
A director at Novartis AG sold 55,000 shares at 90.477CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Danone: 2024 Danone Shareholders’ Meeting: approval of all resolutions Press Release – Paris, April 25, 2024 2024 Danone Shareholders’ Meeting: approval of all resolutions Danone’s Shareholders’ Meeting was held today, chaired by Gilles Schnepp, Chairman of the Board of Directors. 73.58% of Danone’s total outstanding share capital was present or represented in this Shareholders’ Meeting. Danone’s shareholders approved all resolutions submitted to its approval by the Board of Directors, including the statutory and consolidated financial statements for the 2023 fiscal year, and the distri...
DANONE : Assemblée Générale 2024 de Danone : approbation de toutes les résolutions Communiqué de presse – Paris, le 25 avril 2024 Assemblée Générale 2024 de Danone : approbation de toutes les résolutions L’Assemblée Générale des actionnaires de Danone s’est réunie à Paris ce jour, sous la présidence de Gilles Schnepp, Président du Conseil d’Administration. 73,58% du capital social de Danone était présent ou représenté à cette Assemblée Générale. L’Assemblée Générale a approuvé l'ensemble des résolutions proposées par le Conseil d’Administration, notamment les comptes sociaux et les c...
Azelis: Strong margin performance in weak trading results in 3% EBITA beat. BE Semiconductor Industries: 1Q24 results; prolonged downcycle. Coca-Cola Europacific Partners plc: Messy but good. DWS: Record breaking. Flow Traders: Crypto Kings. Fugro: Here we go again. Kinepolis: Weak start to the year, but a bit better than feared. UCB: Changes in the group executive committee. Unilever: Heading in the right direction. Vonovia: Disposal of 4,500 apartments for €700m. Wolters Kl...
A director at Recordati sold 118,000 shares at 51.335EUR and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.